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Abstract 
Approximately 80% of patients diagnosed with acute myeloid leukemia (AML) die as 
a consequence of failure to eradicate the tumor from the bone marrow 
microenvironment. We have recently shown that stroma derived interleukin-8 (IL-8) 
promotes AML growth and survival in the bone marrow in response to AML derived 
macrophage migration inhibitory factor (MIF). In the present study we show that high 
constitutive expression of MIF in AML blasts in the bone marrow is hypoxia-driven and, 
through knockdown of MIF, HIF1α and HIF2α, establish that hypoxia supports AML 
tumor proliferation through HIF1α signalling. In-vivo targeting of leukemic cell HIF1α, 
inhibits AML proliferation in the tumor microenvironment, through transcriptional 
regulation of MIF but inhibition of HIF2α had no measurable effect on AML blast 
survival. Functionally, targeted inhibition of MIF in-vivo improves survival in models of 
AML. Here we present a mechanism linking HIF1α to a pro-tumoral chemokine factor 
signaling pathway and in doing so, we establish a potential strategy to target AML. 
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Introduction 
Survival of patients with acute myeloid leukemia (AML) is poor; two-thirds of young 
adults and 90% of older adults die of their disease (1). Even in patients fit enough to 
be treated with intensive cytotoxic chemotherapies, despite high initial response rates, 
relapse is common and occurs from minimal residual disease harbored within the bone 
marrow microenvironment (2). Improved outcomes require novel treatment strategies 
derived from a better understanding of the biology of the tumor and its 
microenvironment. 
 
Hypoxia is a key microenvironmental factor that influences the biology of the 
hematopoietic stem cell (HSC), as well as leukemic cells within the bone marrow (3-
6). The bone marrow microenvironment is hypoxic and targeting hypoxia inducible 
genes can eliminate cancer stem cells in hematological malignancies (7). The hypoxic 
state is principally maintained by members of the hypoxia-inducible factor (HIF) family. 
Both HIF1α and HIF2α respond to hypoxia; HIF1α responds to acute hypoxia and 
HIF2α to a chronic hypoxic state (8). Despite an increase in the understanding of the 
different pathways regulated by HIF1α and HIF2α, their role in HSC maintenance and 
leukemogenesis remains to be delineated (9, 10). Constitutive HIF1-α expression has 
been detected in normal karyotype AML and was found to be associated with poor 
prognosis (11), moreover, targeting HIF1α in AML cancer stem cells abrogated their 
colony forming activity. Recent data showed that HIF2α silencing impairs long term 
engraftment of HSC and also inhibits proliferation of primary AML in vitro (12). Others 
have shown that HIF2α is high in subsets of both human AML and mouse models of 
AML, and overexpression of HIF2α accelerated disease progression, however this 
study also highlights that patients with high HIF2α expression trend toward  disease 
free survival (13). Together these data describe a complex interplay between hypoxia 
regulated transcription factors HIF1α and HIF2α and there regulatory role in normal 
HSC and AML. 
 
We have previously shown that AML cells constitutively express high levels of 
macrophage migration inhibitory factor (MIF) which drives Interleukin-8 (IL-8) 
expression by the bone marrow mesenchymal stromal cells (BM-MSC), that in turn 
supports AML cell survival and proliferation (14). Furthermore, hypoxia has been 
identified as a potent inducer of the pro-inflammatory cytokine MIF in inflammatory 
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diseases (15, 16) . Specifically, a single nucleotide polymorphism (SNP) mapping to 
a functional hypoxia response element in the MIF locus, prevents induction of MIF by 
hypoxia (17). Together these studies lead us to hypothesize a role for hypoxia in 
regulating MIF survival signals in AML.  
 
The aim of the present study is to determine if there is a connection between the 
hypoxic bone marrow microenvironment and MIF in regulating AML survival. If so, to 
further determine the role of HIF1α and HIF2α in this response and to evaluate the 
functional consequences and potential therapeutic effect of inhibiting such a pathway 
in vivo in AML patient-derived xenograft models. 
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Results 
AML blasts derived from the bone marrow express higher levels of MIF 
compared to blasts in the systemic circulation and spleen 
We have previously shown that primary AML cells from the bone marrow constitutively 
express high levels of MIF which subsequently drives survival signals within the BM 
microenvironment (14). To determine if this is a function of the BM environment, we 
looked at the expression levels of MIF in AML BM samples compared to AML 
peripheral blood (PB) samples (GEO accession number GSE49642) (18). These data 
show that MIF gene expression was significantly higher in AML samples from the BM 
compared to those from PB (Figure 1A). We next carried out qRT-PCR of five patient 
matched primary AML samples (both BM and PB) to show in both samples that AML 
cells from the BM expressed higher levels of MIF than those taken from the PB (Figure 
1B). We then used a patient-derived xenograft (PDX) model, in which 9 primary AML 
patient samples were injected into NSG mice, in order to compare MIF gene 
expression between AML blasts that engrafted in the BM to blasts engrafted in the 
spleen (Figure 1C). Figure 1D confirms that the primary AML reliably engrafted the 
BM and spleen of the NSG mice. Figure 1E shows that MIF had a lower deltaCT or 
dCT (the lower the dCT value the higher the gene expression level) value in the AML 
blasts from the BM compared to blasts from the spleen.  
 
Hypoxia induces MIF in primary AML blasts 
As the BM has been shown to be hypoxic (19-22) and hypoxia has been shown to 
regulate the expression of MIF in various cells (7, 16), we hypothesized that hypoxia 
was responsible for the higher expression of MIF in AML cells located in the BM. In 
2014 Wierenga and colleagues, were able to identify common hypoxia-HIF1α-HIF2α 
gene signatures through the overexpression of HIF1α and HIF2α in CD34+ cord blood 
cells (23), we used the generated HIF1α, HIF2α and hypoxia specific gene lists to 
determine the gene signature in the data set used in figure 1A. Figure 2A and 
supplementary data 1 show that a set of hypoxia-related genes are preferentially 
expressed in AML BM compared to PB, with MIF being a significant gene in this list. 
To determine whether hypoxic conditions could induce expression of MIF in AML 
blasts in vitro we established hypoxic culture conditions either by using the hypoxia-
mimetic agents cobalt chloride (CoCl2) and desferrioxamine (DFO) (which induce 
molecular hypoxic responses with similar kinetics to hypoxia) or by using a hypoxic 
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chamber (1% O2). Figure 2B shows the induction of HIF1a protein in AML cells by 
hypoxia or hypoxia mimic reagents CoCl2 and DFO. MIF mRNA and protein secretion 
were then assayed in experiments on five primary BM-derived AML patient samples. 
Figures 2C and Figure 2D show that CoCl2, DFO and 1% O2 all significantly induced 
MIF mRNA expression and cytokine secretion. Next we sought to determine the 
contribution of HIF1α or HIF2α in regulating the expression of MIF in BM. We 
determined the significantly upregulated/enriched hypoxia, HIF1α and HIF2α genes in 
AML BM samples compared to AML peripheral blood (PB) samples (GEO accession 
number GSE49642).  The analysis showed that MIF expression is part of the HIF1α 
signature but not HIF2α, the VENN diagram (Figure 2E) shows the distribution and 
overlap of the differentially expressed genes identified, there are 57 genes including 
MIF that are regulated by Hypoxia and HIF1α but not HIF2α, based on these findings 
we hypothesize that HIF1α plays a significant role in upregulating MIF in primary AML. 
Figure 2F shows that MIF mRNA expression and protein secretion was not induced in 
non-malignant CD34+ cells under hypoxia. Together these results demonstrate that 
hypoxic regulation of MIF is a tumour specific event.   
 
HIF1α but not HIF2α is stabilized and induces MIF in primary AML blasts in 
response to hypoxia 
To further characterize the role of HIF1α and HIF2α in primary AML blasts, we assayed 
for HIF1α and HIF2α protein expression in AML blasts cultured under normoxic and 
hypoxic conditions. Figure 3A confirms that HIF1α is stabilized under hypoxic 
conditions in primary AML blasts, however, we found that HIF2α was detected in under 
normoxic conditions in U937, OCI-AML3 and 5/6 primary AML tested (Figure 3A, 3B). 
Moreover, only U937 and 1/6 primary sample AML samples showed an increase in 
HIF2a under hypoxic conditions. To further characterize the role of HIF1α in regulating 
MIF and confirm the specificity of the response to HIF1α and not HIF2α, we used 
lentiviral-mediated knockdown (KD) of HIF1α or HIF2α in AML patient blasts. Figure 
3C confirms reduced mRNA expression of HIF1α and HIF2α after infection with HIF1α-
KD and HIF2α-KD lentivirus. Figure 3D shows that HIF1α or HIF2α stabilization is 
reduced in AML blasts under hypoxic conditions in KD cells when compared to control-
KD (ShE-KD) cells.  Figures 3E and Figure 3F show that under hypoxic conditions, 
HIF1α-KD, but not HIF2α-KD, reduced basal levels of secreted MIF in five primary 
AML patient cells and reduced leukemic survival by 65% compared to control cells. 
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However, since the knockdown between HIF1α-KD and HIF2α-KD are not comparable 
we cannot rule out HIF2α involvement in the up-regulation of MIF. Figure 3G shows 
that when we treated HIF1α-KD AML cells with MIF this prevented cell death. Together 
these results demonstrate that HIF1α regulates MIF secretion in AML blasts under 
hypoxic conditions.  
 
HIF1α-regulated MIF functions to promote AML tumor proliferation in vitro 
To understand the importance of HIF1α-regulated MIF for the survival of AML cells 
within the bone marrow microenvironment, we used a lentiviral-mediated knockdown 
(KD) of MIF in our in vitro and in vivo AML assays. Reduced mRNA and protein 
expression of MIF after lentiviral targeting was confirmed prior to functional analysis 
(Figures 4A and 4B). MIF-KD in AML significantly reduced IL-8 mRNA expression from 
BMSC (figure 4C), reduced survival of primary AML cells in vitro,  and compromised 
leukemic colony-forming ability in methylcellulose media assays (Figures 4D and 4E). 
Moreover, knockdown of MIF in AML induced apoptosis (Figure 4F).  
 
Leukemic cell HIF1α functions to promote tumor proliferation in vivo 
In order to track AML disease progression in vivo, we transduced OCI-AML3 cells with 
a luciferase construct that is detectible by bioluminescence (BLI) in live animals. OCI-
AML3-luc cells were then infected with control lentivirus (ShE-KD) or HIF1α-KD or 
MIF-KD lentivirus. NSG mice (6-8 weeks) were injected with 0.5x106 modified OCI-
AML3-luc cells from ShE-KD or HIF1α-KD or MIF-KD cultures. Animals were imaged 
at day 21 and 28 post injection. At both time points mice transplanted with HIF1α-KD 
and MIF-KD cells had lower BLI detection compared to control ShE-KD transplant 
animals (Figures 5A and 5B). Figure 5C shows that NSG mice engrafted with HIF1α-
KD or MIF-KD OCI-AML3-luc cells had significantly increased survival compared to 
control animals (n=4). To show that AML engrafted the bone marrow of NSG mice in 
ShE-KD or HIF1α-KD or MIF-KD we analysed human CD45 expression, the results 
show that in all treatment groups AML was present in the bone marrow after the end 
point of the experiment was reached (Figure 5D).   
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Discussion 
We have previously shown that MIF is an important mediator of AML survival. Here 
we report that hypoxia acting through HIF1α is responsible for the up-regulation of MIF 
and subsequent proliferation and survival of AML in the tumor microenvironment. We 
find that AML in the BM has increased levels of MIF compared to AML in the PB or 
spleen. We show that under hypoxic conditions MIF is up-regulated at both the 
transcriptional and protein levels and functionally the hypoxia/HIF1α/MIF axis 
promotes tumor survival and proliferation of AML within the BM microenvironment in 
vivo.  
 
AML arises from malignant transformation and proliferation of hematopoietic 
progenitor cells in the BM. Under physiologic non-malignant conditions the BM has 
been identified as a hypoxic environment, Fiegl et al. have established that the AML 
BM is also hypoxic (24). In addition, tumor-specific transcriptional programs in AML 
patient samples include an up-regulation of the hypoxic response gene signature (25). 
Moreover, hypoxia has as broader malignant phenotype in the proliferation of solid 
tumor cells in studies of breast, prostate, ovarian and pancreatic cancers (26-28). 
Here, we describe a significant mechanism by which hypoxia is pro-tumoral in the AML 
microenvironment. 
 
We report that a functional consequence of the hypoxic tumor microenvironment in 
AML is the up-regulation of the chemokine MIF. Previously, we have shown that AML-
derived MIF functions to re-program the tumor microenvironment by inducing BM-MSC 
derived IL-8 (29). Interestingly, others have shown that hypoxia regulates MIF 
expression in endothelial cells (30) and vascular smooth muscle cells (15). Moreover, 
hypoxia-induced MIF expression is dependent upon a hypoxia response element 
(HRE) in the 5'UTR of the MIF gene (31). In addition, MIF has recently been shown to 
be up-regulated by hypoxia in several tumor cell types in vitro including breast 
carcinoma cells (31). Interestingly, a number of studies have shown a complex 
relationship between HIF1α and MIF exists in chronic lymphocytic leukemia (CLL) 
(37).  It has been shown that MIF can regulate and be regulated by HIF1α. Moreover, 
MIF regulation has been shown to be both dependent and independent of HIF1α (32). 
In our work on AML, we demonstrate that silencing HIF1α inhibits transcriptional 
regulation of MIF under hypoxia. 
9 
 
 
In our model, knockdown of HIF1α in primary AML cells significantly reduces survival 
of AML cells in culture and significantly increases survival of NSG mice engrafted with 
HIF1α-KD OCI-AML3-luc cells. Previously published results using a murine AML 
model show that genetic deletion of HIF1α has no effect on mouse AML maintenance 
and may accelerate disease development (10). The same group further show that loss 
of HIF1α accelerates murine FLT3-ITD induced myeloproliferation (33). However, 
others have shown that deleting HIF1α in a subset of primary AML leukemic stem cells 
(LSCs) leads to a decrease in sensitivity of these cells to HIF1α inhibition (7). 
Moreover, in their work, Wang and colleagues demonstrated an important role 
for HIF1α in the in vitro colony forming activity of their 7 clinical AML samples with 
experiments using treatment with echinomycin (a HIF1α inhibitor) (7). Echinomycin 
has also been shown to inhibit growth and induce apoptosis of AML cells lines (34). 
Vukovic et al. reported that HIF1α and HIF2α are not required for leukemia stem cell 
maintenance and AML propagation, but they act synergistically to suppress leukemia 
development in mice, in their models, knockout of HIF2α or pharmacological inhibition 
of the HIF pathway in human AML cells has no impact on their survival and proliferation 
under hypoxic conditions (35).  In our studies, we show that HIF2α was detected in 
the majority of AML samples and cell lines under normoxic conditions. Moreover, this 
was not increased under hypoxic condition. We used U937 as a positive control and 
showed that this cell line did increase HIF2a under hypoxia. These results suggest 
that HIF2α is regulated in AML without the need for hypoxia as is the case for other 
tumours (36, 37). Together, there is a lot of conflicting data regarding the regulatory 
role of HIF1α in normal HSC and malignant AML cells. In this manuscript we describe 
a HIF1α driven mechanism which results in up-regulation of MIF in a tumour specific 
manner. Moreover, in-vivo knockdown of HIF1α in AML showed a decreased tumour 
burden and had an increased survival compared to control AML, thus suggesting that 
human AML benefits from the hypoxic bone marrow microenvironment. 
 
Previously published studies observed that HIF2α is constitutively expressed in a 
number of AML subtypes and overexpression studies of HIF2α accelerated myeloid 
leukemia in mice (13). Rouault-Pierre and colleagues show that cells from primary 
AML samples are dependent on the level of HIF2α for their survival and protection 
from apoptosis induced by ER stress. The degradation kinetics of HIF1α and HIF2α 
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also differ although they are ~60% homologous. HIF2α has been shown to be 
detectable in normoxic condition while HIF1α has not (38). Although the similarity in 
homology contributes to overlapping genes/targets regulated by both HIF1α and 
HIF2a, each also regulate a distinctive set of genes in their own right and which is 
supported by our in silico analysis. Moreover, our results also show that HIF2α is 
constitutively expressed under normoxia and hypoxic conditions had little or no effect 
on its expression. Knockdown of HIF2α in primary AML cells did not reduce MIF 
expression or secretion from primary AML. Thus suggesting that MIF is not regulated 
by HIF2α. Our results however, do support studies showing HIF2α expression is 
heterogeneous in AML subtypes (13). 
 
Finally, we found that knocking down MIF significantly reduces AML survival and 
colony forming ability in vitro, moreover, animals transplanted with AML cells post MIF-
KD had significantly improved survival compared to controls, these results in the 
context of recent clinical observations of the use of novel MIF inhibitors in colorectal 
cancer and in solid tumors early phase trials is effective and well tolerated (39, 40), 
suggests the plausibility of a MIF inhibitor trial in patients with AML.  In conclusion, our 
study presents a mechanism linking hypoxia to a chemokine factor pro-tumoral 
signaling pathway in AML microenvironment. In doing so we establish a potential 
strategy to target AML, a hypoxia-driven malignancy.  
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Materials and Methods 
Materials 
Anti-HIF1α antibody was purchased from BD Biosciences (Oxford, UK). Anti-HIF2α 
was purchased from (Novus Bio, Cambridge, UK Cat: NB100-122SS) IgG-FITC, IgG-
PE, IgG-APC, anti-CD34-PE, anti-CD33-APC and anti-CD45-FITC antibodies were 
purchased from Miltenyi Biotec (Bergisch Gladbach, Germany Cat. 130098847, 
130098845, 130092214, 130098139, 130098043, 130098864). Recombinant human 
MIF, and MIF ELISA were purchased from R&D Systems (Abingdon, UK). All other 
reagents were obtained from Sigma-Aldrich (St Louis, MO, USA), unless otherwise 
indicated 
 
Methods 
Cell cultures 
The AML derived cell lines were obtained from the European Collection of Cell 
Cultures (ECCC) where they are authenticated by DNA fingerprinting. All cell lines are 
tested for mycoplasma contamination. Primary AML blasts were obtained from patient 
bone marrow or blood following informed consent and under approval from the United 
Kingdom Health Research Authority (LRECref07/H0310/146). For primary AML and 
BMSC cell isolation, heparinized bone marrow and blood were isolated by density 
centrifugation using Histopaque which has been previously described (41). Primary 
AML and BMSC cells and cell lines were cultured in growth medium comprising DMEM 
and 10% FBS and 1% L-glutamine at 5% CO2 at 37 °C.  
 
Hypoxic assays 
For hypoxic cultures, cells were incubated in a hypoxia chamber (Billups-Rothenberg 
Inc, Del Mar, USA) with 1% O2/ 5% CO2/ N2 200 bar. The chamber was incubated at 
37 °C for indicated times. Control cell cultures, not deprived of oxygen, were incubated 
under normal conditions. Cobalt chloride (CoCl2) and desferrioxamine (DFO) were 
added to cell cultures at indicated concentrations and time points.  
 
Clonogeneic methylcellulose assay 
AML blasts were plated in complete methylcellulose medium supplemented with 
cytokines (R&D Systems, Abingdon, UK) at a density of 1x103. Light microscopy was 
used to visualize and count colonies at days 10-14. 
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Flow cytometry 
Cells were collected by centrifugation for 3 minutes at 2,000 rpm, then washed and 
resuspended in phosphate-buffered saline (PBS), incubated for 5 minutes with the 
FcR blocking reagent and then stained with anti-CD45, anti-CD34 or anti-CD33 or 
isotype control. Analysis was performed on a CyFlow® Cube 6 flow cytometer 
(Sysmex, Milton Keynes, UK). 
 
Cell viability assay 
Cell viability was measured using the Cell Titer-Glo Luminescent Cell Viability Assay 
kit (Promega, Southampton, UK) according to the manufacturer’s instructions.  
 
RNA extraction and real-time PCR 
ReliaPrep RNA extraction kit from Promega (Southampton, UK) was used to extract 
total RNA. PCRBIO cDNA synthesis kit (PCR Biosystems, London, UK) was used to 
generate cDNA from total RNA. Relative quantitative real-time PCR using qPCRBIO 
SyGreen Mix (PCR Biosystems) was performed as previously described (41). mRNA 
expression was normalized against B-actin mRNA expression. 
 
Western immunoblotting and ELISAs 
Briefly, whole cell lysates were extracted and SDS PAGE gel electrophoresis 
separation performed as previously described (42). Western blot analysis performed 
with anti-HIF1α and anti- HIF2α antibody, membranes were re-probed for B-actin as a 
loading control. MIF chemokine expression in the media we used target-specific MIF 
ELISA (R&D Systems). 
 
shRNA silencing of MIF, HIF1α and HIF2α 
Mission shRNA targeted lentivirus plasmids (Sigma-Aldrich) were used to generate 
lentivirus as previously described (43). OCI-AML3 cells were infected with pCDH-
luciferase-T2A-mCherry (44). OCI-AML3 cells expressing mCherry (OCI-AML3-luc) 
were sorted on a FACSAria (BD Biosciences). The MIF-KD and the HIF1α-KD in vivo 
experiments were carried simultaneously, therefore the same control-KD (ShE-KD) 
mice were used for both MIF-KD and HIF1α-KD mice (Figure 2G-I and Figure 3E-G). 
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OCI-AML3-luc xenograft model 
NOD.Cg-Prkdcscid IL2rgtm1Wjl/SzJ (NSG) mice from The Jackson Laboratory (Bar 
Harbor, ME, USA) were used for this study.  All animal experiments were performed 
in accordance with UK Home Office approvals and regulations and with approval from 
the Animal Welfare and Ethical Review Board of the University of East Anglia. 0.5x106 
OCI-AML3-luc cells were intravenously injected into the tail vein of non-irradiated 6-8-
week-old NSG mice. When clinical signs of illness became apparent, mice were 
sacrificed. Bone marrow (BM) and spleen were harvested and analyzed for human 
CD45 expression. No animals were excluded from experiments and no randomization 
was used. No blinding was used.  
 
Patient-derived xenograft model 
Primary AML were cultured in vitro as previously described (45). 2x106 viable AML 
cells were injected into the tail vein of non-irradiated 6-8-week-old female NSG mice. 
When clinical signs of illness became apparent, mice were sacrificed.  BM and spleen 
were harvested and analyzed for human CD33 and CD45.  
 
Bioinformatic analysis 
Publicly available RNA sequencing data were downloaded for a panel of 43 
AML patients, which comprised 22 AML samples obtained from peripheral blood and 
21 AML samples obtained from BM aspirate (Gene  Expression  Omnibus  Accession  
ID: GSE49642). RPKM data for MIF were extracted and processed further by first 
replacing zero-valued entries with one followed by logarithmic transformation to the 
base 2.21. MIF RPKM values for blood and bone marrow samples were compared 
with a Wilcoxon rank-sum test. Data were extracted for genes that have been shown 
to be upregulated as a result of HIF1α overexpression, HIF2α overexpression and 
hypoxia (23) .These data were processed further by first replacing zero-valued entries 
with one, and followed by logarithmic transformation to the base 2. 
 
Statistical analyses 
For Western blotting, data are representative images of three independent 
experiments. Calculations were made using the software G*Power.  The Mann-
Whitney U test was used to compare test groups where stated in the legends. Results 
where p<0.05 were considered statistically significant and denoted by *. Results 
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represent the mean ± standard deviation of four or more independent experiments. 
We generated statistics with Graphpad Prism5 software (Graphpad, San Diego, CA, 
USA). 
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Figure legends:  
 
Figure 1. Bone marrow derived AML express higher level of MIF. (A) MIF gene 
expression (expressed in log2 RPKM values) was obtained from GSE49642 for 22 
peripheral blood (PB) and 21 bone marrow (BM) AML patient samples. p-value was 
obtained by Wilcoxon rank-sum test. Line denotes the median value. (B) RNA was 
extracted from AML derived from the BM and PB from matched patients.  MIF mRNA 
expression was determined by qPCR and normalized to B-actin. (C) Primary AML 
blasts were isolated from BM and injected into the tail vein of NSG mice. (D) and (E) 
2x106 primary AML cells (9 patient AML) were injected into NSG mice. (D) Engraftment 
was measured using human CD33 and human CD45, in the dot plot each AML 
engraftment into NSG mice is shown for bone marrow and spleen. (E) RNA was 
extracted from AML from the BM and spleen. RNA was analysed for MIF mRNA using 
human specific primers. mRNA differences are presented as delta cycle threshold 
(dCT), normalized to human B-actin.  
 
Figure 2. Hypoxia induces MIF expression in Primary AML blasts. (A) Heatmap 
of genes that are differentially expressed between bone marrow and peripheral blood 
AML samples (adjusted P < 0.05, Significance Analysis of Microarrays) (data from 
GSE49642). Only genes that are upregulated under hypoxia are displayed (23). 
Samples (columns) are grouped according to the type of sample: bone marrow (black) 
or peripheral blood (grey). The expression of individual genes (rows) across the 
dataset is represented by mean-centred log2 expression values. The genes are 
ordered from top to bottom by descending fold change. (B) AML cells were treated 
with CoCl2 (100uM), DFO (150uM) or cultured under hypoxic conditions (1% O2) for 4 
hours, then protein was extracted and Western blotting performed.  (C) Primary AML 
cells were treated with CoCl2 (100uM) or DFO (150uM) for 4 hours or cultured under 
hypoxic conditions for 24 hours, RNA was extracted and MIF mRNA expression was 
determined with RT-PCR. Data represented as mean ± standard deviation (n=5). 
(p<0.05)  (D) Media was collected from the respective conditions described in (B) and 
MIF protein secretion was determined by target-specific ELISA, Data represented as 
mean ± standard deviation (n=5). (p<0.05) (E) Venn diagram showing overlaps in 
genes up regulated upon induction of hypoxia, overexpression of HIF1α and HIF2α. 
(F) Non-malignant CD34+ cells were cultured under hypoxic conditions for 24 hours.  
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Culture media was assayed for MIF cytokine secretion and RNA was extracted and 
MIF mRNA expression was determined with RT-PCR. Data represented as mean ± 
standard deviation (n=5) (p<0.05). 
 
Figure 3. HIF1α but not HIF2α regulates MIF mRNA and protein expression in 
AML blasts. (A) OCI-AML3 and primary AML blasts were cultured under hypoxic 
conditions for 4 hours to detect HIF1α and 12 hours to detect HIF2α, protein was 
extracted and Western blotting performed. (B) OCI-AML3, U937 and primary AML 
blasts were cultured under hypoxic conditions for 6 hours to detect HIF2α, protein was 
extracted and Western blotting performed. Lentiviral knockdown (KD) of HIF1α or 
HIF2α in AML blasts was determined by RT-PCR for mRNA expression. Data 
represented as mean ± standard deviation (n=5) (C) and Western blotting for protein 
expression (D) under hypoxic conditions. (E) MIF protein expression in culture media 
from HIF1α or HIF2α-KD blasts compared to control-KD (ShE) cells was determined 
by ELISA. Data represented as mean ± standard deviation (n=5). (F) Control-KD (ShE) 
and HIF1α or HIF2α KD AML blasts were cultured for 10 days post-infection in hypoxia; 
cell survival was measured using CellTiter-Glo Luminescent Cell Viability Assay. Data 
represented as mean ± standard deviation (n=5). (G) Control-KD (ShE) and HIF1α or 
HIF2α KD primary AML blasts were cultured for 24 hours in hypoxia while treated with 
MIF (100ng/ml); cell survival was measured using CellTiter-Glo Luminescent Cell 
Viability Assay. Data represented as mean ± standard deviation (n=5) (p<0.05). 
 
Figure 4. MIF regulates AML survival and colony formation.  Lentiviral KD of MIF 
in OCI-AML3-luc cell line and primary AML blast was confirmed by RT-PCR (A) and 
protein by ELISA (B). (C) ShE-KD and MIF-KD Primary AML blasts were cultured with 
BMSC for 4 hours, then IL-8 mRNA expression in BMSC was confirmed by RT-PCR. 
(D) ShE-KD and MIF-KD cells were cultured in basal media for 10 days post infection 
in hypoxia; cell survival was measured using CellTiter-Glo Luminescent Cell Viability 
Assay. (E) Colony-forming assays of ShE-KD and MIF-KD cells were performed in 
methylcellulose media. (F) Apoptosis assays of ShE-KD and MIF-KD cells were 
performed using annexin V and propidium iodide. Data represented as mean ± 
standard deviation (n=5) (p<0.05). 
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Figure 5. Targeting HIF1α and MIF in AML xenograft model. (A-D) 0.5x106 control-
KD (ShE) OCI-AML3-luc and HIF1α-KD or MIF-KD OCI-AML3-luc cells were injected 
into NSG mice (n=4 for each KD). NSG mice were monitored for disease progression 
using bioluminescence and sacrificed upon signs of disease. (A) Bioluminescence 
images of recipient mice, control-KD (ShE) and HIF1α-KD (HF) OCI-AML3-luc cells 
on day 21 and day 28 respectively. (B) The mean bioluminescence intensity of each 
image was determined with Image J software. (C) Kaplan-Meier survival curves for 
NSG mice injected with OCL-AML3-luc HIF1α-KD cells or OCI-AML3-luc control-KD 
cells. (D) Chimerism data showing engraftment of OCI-AML3 which was measured 
using human CD45. In the dot plot each AML engraftment into NSG mice is shown for 
control-KD (ShE) and HIF1α-KD.  
